Stock Information

Investor and Media Relations

Anthony Marciano
Head of Corporate Communications
Seelos Therapeutics, Inc.
anthony.marciano@seelostx.com

Offices
Seelos Therapeutics, Inc.
300 Park Avenue
New York, NY 10022

Incorporated
Nevada

Entity type
Corporation

Identifiers
CIK:1017491
IRS:870449967

Receive Email Alerts

Overview

Seelos Therapeutics, Inc. (Nasdaq: SEEL) is a responsibly-driven company focused on achieving the most efficient development of products that address significant unmet needs in CNS disorders and in rare diseases.

Stock History

On January 24, 2019, Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced the completion of its previously disclosed merger with Apricus Biosciences, Inc.

Seelos Therapeutics, Inc. began trading on January 24, 2019 on The Nasdaq Capital Market under the ticker symbol “SEEL”.

Seelos maintains its headquarters in New York, New York and is led by Chairman, Founder, and Chief Executive Officer, Raj Mehra, Ph.D.

Seelos rang the Nasdaq Stock Market opening bell on August 12, 2019 at 9:30 am E.T., at the Nasdaq MarketSite in Times Square.

Stock Chart